-
EP3706741
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3706741
| EP3706741 - PHARMACEUTICAL COMPOSITION AND USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 03.02.2023 Database last updated on 03.08.2024 | |
| Former | Request for examination was made Status updated on 14.08.2020 | ||
| Former | The international publication has been made Status updated on 30.05.2020 | Most recent event Tooltip | 03.02.2023 | Application deemed to be withdrawn | published on 08.03.2023 [2023/10] | Applicant(s) | For all designated states Ascentage Pharma (Suzhou) Co., Ltd. Unit 701, Building B7, 218 Xinghu Street Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | For all designated states Ascentage Pharma Group Corp Limited 9/F., Wah Yuen Building 149 Queen's Road Central Hong Kong / CN | [2020/38] | Inventor(s) | 01 /
YANG, Dajun Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 02 /
ZHAI, Yifan Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 03 /
FANG, Douglas Dong Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | 04 /
TAO, Ran Unit 701, Building B7 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu 215000 / CN | [2020/38] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [N/P] |
| Former [2020/38] | Lavoix Bayerstrasse 83 80335 München / DE | Application number, filing date | 19887513.0 | 22.11.2019 | [2020/38] | WO2019CN120144 | Priority number, date | WO2018CN117270 | 23.11.2018 Original published format: PCT/CN2018/117270 | CN201911132493 | 19.11.2019 Original published format: CN201911132493 | [2020/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020103921 | Date: | 28.05.2020 | Language: | EN | [2020/22] | Type: | A1 Application with search report | No.: | EP3706741 | Date: | 16.09.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.05.2020 takes the place of the publication of the European patent application. | [2020/38] | Search report(s) | International search report - published on: | CN | 28.05.2020 | (Supplementary) European search report - dispatched on: | EP | 25.02.2022 | Classification | IPC: | A61K31/437, A61K45/06, A61K31/453, A61K31/519, A61P35/00, A61P35/02, A61K31/416, A61K31/4184 | [2022/13] | CPC: |
A61K31/416 (EP);
A61K31/444 (EP,CN);
A61K31/496 (EP,CN,US);
A61K31/4184 (EP);
A61K31/437 (EP,US);
A61K31/453 (EP,US);
A61K31/4545 (EP,CN);
A61K31/519 (EP,US);
A61K31/635 (EP);
A61K45/06 (EP,CN,US);
A61P21/00 (EP,CN);
A61P3/04 (EP,CN);
A61P35/00 (EP,CN);
A61P35/02 (EP,CN);
A61P35/04 (US);
| C-Set: |
A61K31/444, A61K2300/00 (EP,CN);
A61K31/453, A61K2300/00 (EP);
A61K31/4545, A61K2300/00 (CN,EP);
A61K31/496, A61K2300/00 (CN,EP); |
| Former IPC [2020/38] | A61K31/437, A61K45/06, A61K31/453, A61K31/519, A61P35/00, A61P35/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/38] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG UND VERWENDUNG DAVON | [2020/38] | English: | PHARMACEUTICAL COMPOSITION AND USE THEREOF | [2020/38] | French: | COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉE | [2020/38] | Entry into regional phase | 10.06.2020 | National basic fee paid | 10.06.2020 | Search fee paid | 10.06.2020 | Designation fee(s) paid | 10.06.2020 | Examination fee paid | Examination procedure | 10.06.2020 | Amendment by applicant (claims and/or description) | 10.06.2020 | Examination requested [2020/38] | 27.09.2022 | Application deemed to be withdrawn, date of legal effect [2023/10] | 19.10.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/10] | Fees paid | Renewal fee | 12.10.2021 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 30.11.2022 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XY]WO2018027097 (UNIV MICHIGAN REGENTS [US]) [X] 1-6,11-15 * paragraph [0206]; claims 1-60; table 1; compounds 1-66 * [Y] 7-10; | [Y]WO2015130585 (MERCK SHARP & DOHME [US], et al) [Y] 7-10 * claims 1-22 *; | [Y] - BOGENBERGER JAMES ET AL, "Combined venetoclax and alvocidib in acute myeloid leukemia", ONCOTARGET,, (20171103), vol. 8, no. 63, doi:10.18632/ONCOTARGET.22284, pages 107206 - 107222, XP002787435 [Y] 7-10 * abstract * DOI: http://dx.doi.org/10.18632/oncotarget.22284 |